What advantages are there for drug developers to choose advanced dosage forms for new molecules in their development pipelines? Or, are advanced dosage forms more suitable for expanding companies’ product portfolios with the existing molecules? How can innovators select the dosage forms and technologies that are the most suitable for oral delivery?

To answer these questions, FiercePharma and Catalent recently conducted a survey to understand the factors affecting innovators’ decision to choose a particular dosage form. In this webinar, industry experts will present the survey results and share insights on how advanced dosage forms can address the specific attributes of a molecule, and patients’ needs.

Register for the webinar to learn about the tools and technologies for creating dosage forms such as orally disintegrating tablets (ODTs), multi-particulates, and modified release formulations.

Key learnings include:
  • How to choose the dosage form and technologies to optimize the molecule to meet patients’ needs
  • The value of advanced dosage forms to both new and existing molecules
  • Understanding the tools and techniques for creating advanced dosage forms

Featured Speakers

Ralph Lipp, Ph.D.

President and CEO
Lipp Life Sciences LLC

Ralph Lipp is focused on helping clients elevate innovation and create value. He was previously the chief scientific officer at Noven Pharmaceuticals and held various R&D leadership positions at Eli Lilly and Schering. Ralph has over 25 years of experience in the drug delivery industry with more than 140 scientific publications and 20+ patents covering five marketed medicines with aggregate peak annual sales exceeding $1 billion.

Ralph Gosden

Head of Product Development

Ralph Gosden is based at Swindon, UK and oversees Catalent’s Zydis® Fast Dissolve Tablet technology platform scale up and strategic project capabilities.  In a career spanning over 20 years, Ralph has worked in all the major disciplines in pharmaceutical R&D from feasibility through scale up and validation and has extensive experience understanding formulation and process development for oral dose forms.

Ronald Vladyka

Director of Formulation Research and Development

Ronald Vladyka, R.Ph., has been with Catalent for over 10 years.  His professional career spans over 25 years in various product development and drug delivery positions including roles at Aegerion Pharmaceuticals, FMC, and Roche.  Areas of expertise include development of drug delivery technologies and design and formulation development of modified release doses. 

Nick Taylor


Nick Taylor is a writer with more than 10 years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including FierceBiotech and Nature's BioPharma Dealmakers.


Register now for this webinar